New Enterprise Associates and Bioelectronic Medicine News

This is selected news for New Enterprise Associates and Bioelectronic Medicine, which are filed under Capital Firms and Healthcare Topics, respectively.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/14/2019 SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019
... medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, Sightline Partners, GlaxoSmithKline's Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic ...
Globe Newswire
6/3/2019 SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019
VALENCIA, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that results from its U.S. pilot Investigational Device Exemption (IDE) study in rheumatoid arthritis (RA) have been accepted for oral and poster presentation at the European Congress ...
Benzinga
6/3/2019 SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019
... medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, sightline Partners, glaxosmithkline's Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic ...
financialbuzz.com
5/22/2019 SetPoint Medical to Present at Guggenheim 2019 MedTech Disruptors Summit
VALENCIA, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, announced today that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, has been invited and is scheduled to present at the 2 nd Annual MedTech Disruptors Summit hosted by ...
Benzinga
5/22/2019 SetPoint Medical to Present at Guggenheim 2019 MedTech Disruptors Summit
... medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, SightLine Partners, GlaxoSmithKline's Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic ...
financialbuzz.com
5/21/2019 SetPoint Medical Reports New Data Demonstrating its Bioelectronic Medicine Effectively Reduces Crohn’s Disease Activity
Valencia, CA - May 20, 2019 - SetPoint Medical , a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced new positive clinical data from a proof-of-concept study evaluating its bioelectronic medicine approach for the treatment of Crohn's Disease, a debilitating condition caused by inflammation of the ...
BioSpace
5/20/2019 SetPoint Medical Reports New Data Demonstrating its Bioelectronic Medicine Effectively Reduces Crohns Disease Activity
... medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, SightLine Partners, GlaxoSmithKline's Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic ...
financialbuzz.com
4/30/2019 SetPoint Medical to Present at Bank of America Merrill Lynch Health Care Conference 2019
... America Merrill Lynch representative, or Emma Poalillo of The Ruth Group at [email protected] . About SetPoint Medical SetPoint Medical is a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. SetPoint Medical's bioelectronic medicine platform is intended to offer patients and providers a treatment ...
Globe Newswire
4/30/2019 SetPoint Medical to Present at Bank of America Merrill Lynch Health Care Conference 2019
... medicine platform that stimulates the vagus nerve to activate the inflammatory reflex to produce a systemic immune-restorative effect. Current investors in the company include New Enterprise Associates (NEA), Morgenthaler Ventures, Topspin Partners, SightLine Partners, GlaxoSmithKline's Action Potential Venture Capital and Boston Scientific as well as an additional undisclosed strategic ...
tmcnet.com
11/30/2017 Term Sheet – Thursday, November 30 | Fortune
... 2.3 billion valuation. Baillie Gifford led the round, and was joined by investors including Revolution Growth and GreatPoint Ventures. * ElectroCore , a Basking Ridge, N.J.-based bioelectronic medicine healthcare company, raised more than $70 million in Series B funding. Core Ventures led the round. * H2O.ai, a Mountain View, Calif.-based company ...
Fortune